Kymera Therapeutics

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

KYM-001 causes potent and selective IRAK4 protein knockdown and regression of OCI-LY10 tumor xenografts, both alone and in combination with BTK inhibition Cambridge, Mass. (June 19, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create